Literature DB >> 3330790

Glycine-cysteine substitution at codon 13 of the N-ras proto-oncogene in a human T cell non-Hodgkin's lymphoma.

A Wodnar-Filipowicz1, H P Senn, J Jiricny, E Signer, C Moroni.   

Abstract

Tumor-derived DNA from a non-Hodgkin's (T cell) lymphoma patient, assayed by NIH3T3 transfection followed by inoculation of cells into nude mice, was found to contain an activated N-ras proto-oncogene. The mode of activation was determined by hybridization with N-ras-specific oligonucleotide probes detecting mutations at codons 12, 13 and 61. A transversion in codon 13 (GGT----TGT) resulting in replacement of glycine13 by cysteine13 in ras p21 protein was found. The mutation was detected in DNA from mouse tumors induced by transfected NIH3T3 cells and in DNA from patient tumor lymphoblasts. The patient was heterozygous for this mutation. These data identify the first base of codon 13 as a novel mutation site in ras genes and indicate that cysteine at position 13 of the ras p21 is a transforming substitution.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3330790

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  2 in total

1.  Analysis of RAS oncogene mutations in human lymphoid malignancies.

Authors:  A Neri; D M Knowles; A Greco; F McCormick; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

2.  A v-H-ras-dependent hemopoietic tumor model involving progression from a clonal stage of transformation competence to autocrine interleukin 3 production.

Authors:  A P Nair; I D Diamantis; J F Conscience; V Kindler; P Hofer; C Moroni
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.